Posted: 14 December
INOVIQ Limited is pleased to announce that the Ovarian Cancer 97 study (OC97) has been completed by the Centre for Clinical Research, The University of Queensland (UQ), confirming the utility of EXO-NET for EV biomarker discovery and generation of a multivariate index assay (MIA) with over 90% accuracy for the detection of early-stage ovarian cancer.
In April 2022, it was announced that INOVIQ and UQ commenced an evaluation of EXO-NET that upon success would enable UQ to use EXO-NET in the further development of its ovarian cancer screening test. The objective of the OC97 study was to establish that EXO-NET is fit-forpurpose in ovarian cancer EV) biomarker (microRNA and protein) discovery and development of an EV-based ovarian cancer diagnostic. INOVIQ worked with UQ’s commercialisation company UniQuest to negotiate the Umbrella Research and Option Agreement (Agreement) announced in April 2022. Under this Agreement, INOVIQ holds the exclusive option to license UQ’s intellectual property in the EV-based ovarian cancer test, worldwide.
